Ivermectin futile for mild to moderate COVID-19, study finds

Early treatment with the antiparasitic drug ivermectin does not lower the risk of severe disease when given to patients with mild to moderate COVID-19, according to a study today in JAMA Internal Medicine.

And a related study in the same journal finds connections between prescribing patterns for ivermectin and hydroxychloroquine by political-party vote share in 2020.

Lack of efficacy, more adverse events

Doctors at 20 Malaysian government hospitals and a COVID-19 quarantine center conducted an open-label, randomized clinical trial on the use of ivermectin in the first week of COVID-19 symptom onset in hospitalized adults 50 years and older with mild or moderate illness and underlying medical conditions. The study took place from May 31 to Oct 25, 2021.

Average patient age was 62.5 years, 54.5% were women, 51.8% had received two doses of a COVID-19 vaccine, 75.3% had high blood pressure, 53.5% had diabetes, 37.6% had abnormal cholesterol levels, and 23.9% were obese.

Patients were randomly assigned in a 1:1 ratio to receive oral ivermectin daily for 5 days plus standard care (241 patients) or standard care only (249). Standard care consisted of treatment of symptoms and monitoring of clinical findings, laboratory test results, and chest imaging for signs of disease progression.

Severe disease was defined as hypoxia (low oxygen levels) requiring the use of supplemental oxygen to maintain oxygen saturation at 95% or higher.

Fifty-two of 241 patients in the ivermectin group (21.6%) and 43 of 249 patients in the standard-care-only group (17.3%) became severely ill (relative risk [RR], 1.25; 95% confidence interval [CI], 0.87 to 1.80).

There were no significant differences between the two groups in time to symptom resolution or rates of mechanical ventilation, intensive care unit (ICU) admission, 28-day in-hospital death, or adverse events. Four ivermectin recipients (1.7%) required mechanical ventilation, compared with 10 (4.0%) in the standard-care group (RR, 0.41; 95% CI, 0.13 to 1.30).

Six patients (2.4%) in the ivermectin group were admitted to an ICU, versus 8 (3.2%) in the control group (RR, 0.78; 95% CI, 0.27 to 2.20), and 3 ivermectin recipients (1.2%) and 10 controls (4.0%) died by 28 days (RR, 0.31; 95% CI, 0.09 to 1.11).

Forty-four patients (9.0%) had 55 adverse events, 33 of them in the ivermectin group. The most common adverse event was diarrhea, occurring in 14 (5.8%) in the ivermectin group and 4 (1.6%) in the standard-care group.

Five serious adverse events—four in the ivermectin group—were reported. Two patients had a heart attack, one had severe anemia, and one went into shock owing to fluid loss from severe diarrhea, while one in the control group had arterial bleeding in the abdomen. Adverse events led six patients to stop taking ivermectin and three to withdraw from the study. Thirteen patients (2.7%) died, most from COVID-19 pneumonia; no deaths were attributed to ivermectin.

"The notably higher incidence of AEs [adverse events] in the ivermectin group raises concerns about the use of this drug outside of trial settings and without medical supervision," the researchers wrote.

The authors noted that ivermectin may appear to be an attractive alternative to expensive antiviral medications in resource-limited regions such as Malaysia because it is inexpensive, easy to use, and broadly available.

However, the World Health Organization recommends against its use outside of clinical trials, and it is not US Food and Drug Administration (FDA)-approved for the prevention or treatment of COVID-19. Indeed, the Centers for Disease Control and Prevention (CDC) confirmed with the American Association of Poison Control Centers that reports of ivermectin-related adverse events increased in 2021 relative to before the pandemic.

"The study findings do not support the use of ivermectin for patients with COVID-19," the authors concluded.

Ivermectin, hydroxychloroquine Rx by political affiliation

In a related observational study, a team led by Harvard researchers examined medical claims from all nonhospitalized adult patient visits in counties with 50 or more residents in the OptumLabs Data Warehouse from January 2019 through December 2020. A total of 18,555,844 participants were included; average age was 49.1 years, and 52.3% were women.

The team also assessed county-level rates of new prescriptions for the antimalarial medication hydroxychloroquine and ivermectin per 100,000 enrollees and two control medications, methotrexate sodium and albendazole. The control drugs have similar clinical applications as hydroxychloroquine (methotrexate) and ivermectin (albendazole) but are not proposed as COVID-19 therapies, the authors said.

After dividing county-level Republican vote in the 2020 presidential election into quartiles, the researchers modeled the change in new prescriptions between residents of the highest, versus the lowest, quartiles.

After a spike and decline in hydroxychloroquine prescribing in March and April 2020, new prescription volume for that drug was higher in June through December 2020 than in 2019 (42.0 new prescriptions per 100,000 participants vs 20.0). Ivermectin prescribing volume was highest in December 2020, at 72.3 new prescriptions per 100,000 participants versus 10.6 in 2019. Over the same period, there were no meaningful changes in prescribing volume for the control drugs.

Prescribing for hydroxychloroquine and ivermectin did not differ from county-level Republican vote share quartile in 2019, but in early 2020, prescribing volume was lower in counties with the highest Republican vote share than in those with the lowest share (-25.1 per 100,000 participants in April).

But after June 2020, when the FDA revoked emergency use authorization (EUA) for hydroxychloroquine for lack of efficacy in COVID-19 and a link to adverse events, prescribing volume for that drug was significantly higher in the highest Republican vote share counties versus the lowest (+42.4 new prescriptions per 100,000 enrollees)—146% higher than 2019 baseline volume.

In December 2020, prescribing volume for ivermectin was significantly higher in the highest versus the lowest Republican vote share counties (+80.9 new prescriptions per 100,000), 964% higher than the 2019 baseline. There was no link between prescribing volume for methotrexate and albendazole and Republican vote share in 2020.

"Our findings are consistent with the hypothesis that US prescribing of hydroxychloroquine and ivermectin during the COVID-19 pandemic may have been influenced by political affiliation," the researchers wrote.

"Because political affiliation should not be a factor in clinical treatment decisions, our findings raise concerns for public trust in a nonpartisan health care system."

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»